We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.42%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$137M
AUM Growth
-$1.43M
Cap. Flow
+$3.85M
Cap. Flow %
2.8%
Top 10 Hldgs %
73.24%
Holding
64
New
1
Increased
15
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
OVV icon
Ovintiv
OVV
+$2.58M
2
PRTA icon
Prothena Corp
PRTA
+$1.77M
3
PHR icon
Phreesia
PHR
+$1.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$933K
5
BDSX icon
Biodesix
BDSX
+$908K

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$2.06M
2
BMY icon
Bristol-Myers Squibb
BMY
+$2M
3
AMRN
Amarin Corp
AMRN
+$647K
4
UTHR icon
United Therapeutics
UTHR
+$610K
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$518K

Sector Composition

Rank Sector Weight
1 Healthcare 93.73%
2 Energy 3.94%
3 Consumer Staples 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$56M 40.76%
727,785
-26,321
-3% -$2M
ELUT icon
2
Elutia
ELUT
$42M
$10M 7.29%
1,418,123
+200
+0% +$1.29K
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$8.31M 6.04%
85,240
-4,000
-4% -$369K
QDEL icon
4
QuidelOrtho
QDEL
$1.19B
$5.96M 4.33%
61,306
+1,622
+3% +$165K
FHTX icon
5
Foghorn Therapeutics
FHTX
$305M
$3.87M 2.82%
284,843
-9,300
-3% -$120K
OVV icon
6
Ovintiv
OVV
$16.2B
$3.72M 2.71%
84,200
+50,000
+146% +$2.58M
UTHR icon
7
United Therapeutics
UTHR
$22.7B
$3.54M 2.57%
15,000
-3,000
-17% -$610K
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$4.38B
$3.51M 2.56%
249,400
+50,000
+25% +$933K
BDSX icon
9
Biodesix
BDSX
$209M
$2.93M 2.13%
90,571
+27,933
+45% +$908K
PRTA icon
10
Prothena Corp
PRTA
$453M
$2.78M 2.03%
102,548
+60,570
+144% +$1.77M
CLR
11
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$2.52M 1.84%
38,600
– –
ALBO
12
DELISTED
Albireo Pharma Inc
ALBO
$2.24M 1.63%
113,000
– –
AXDX
13
DELISTED
Accelerate Diagnostics
AXDX
$2.24M 1.63%
225,239
– –
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.19M 1.59%
15,000
+1,000
+7% +$128K
PHR icon
15
Phreesia
PHR
$662M
$2.07M 1.5%
82,700
+72,700
+727% +$1.6M
MASI
16
DELISTED
Masimo
MASI
$2M 1.45%
15,280
+6,000
+65% +$803K
ALKS icon
17
Alkermes
ALKS
$8.79B
$1.49M 1.08%
50,000
– –
GOSS icon
18
Gossamer Bio
GOSS
$83.2M
$1.33M 0.97%
159,088
+30,000
+23% +$232K
HROW icon
19
Harrow
HROW
$1.74B
$1.31M 0.95%
180,000
– –
KPTI icon
20
Karyopharm Therapeutics
KPTI
$216M
$1.22M 0.88%
17,955
– –
CORT icon
21
Corcept Therapeutics
CORT
$9.72B
$1.19M 0.86%
50,000
– –
CYTK icon
22
Cytokinetics
CYTK
$10.9B
$982K 0.71%
25,000
– –
AVEO
23
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$918K 0.67%
140,000
– –
PXD
24
DELISTED
Pioneer Natural Resource Co.
PXD
$848K 0.62%
3,800
– –
ETRN
25
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$846K 0.62%
133,050
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Birchview Capital held 64 positions worth $137M, down 1% from $139M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Birchview Capital's Q2 2022 filing shows 1 new, 15 increased, 6 reduced and 4 closed positions. Its largest new stake was Xenon Pharmaceuticals: 10,000 shares worth $304K. The largest sale was Biogen, an estimated $2.06M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2022 buy was Xenon Pharmaceuticals: 10,000 shares worth $304K.
  • Birchview Capital added most to Ovintiv in Q2 2022, an estimated $2.58M increase.
  • Birchview Capital's biggest Q2 2022 reduction was Bristol-Myers Squibb, cutting an estimated $2M.
  • Birchview Capital fully exited Biogen in Q2 2022, selling an estimated $2.06M.
  • Birchview Capital's ten largest holdings make up 73% of its $137M portfolio in Q2 2022.
  • Birchview Capital opened 1 new position and closed 4 in Q2 2022.
  • Birchview Capital's portfolio value fell 1% quarter-over-quarter to $137M.

Based on Birchview Capital's 13F filing for Q2 2022, filed 12 Aug 2022.